| Nov 15 |
Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals’ Proposals to Authorize the Sale of its Avenova Brand
|
| Nov 6 |
NovaBay accepts higher PRN offer, says Refresh deal no longer superior
|
| Nov 6 |
NovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase Price
|
| Oct 29 |
NovaBay Pharmaceuticals receives unsolicited offer from Refresh Acquisitions
|
| Oct 29 |
NovaBay Pharmaceuticals Board Determines Unsolicited Offer is Superior to Asset Purchase Agreement with PRN Physician Recommended Nutriceuticals, LLC
|
| Sep 20 |
Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals
|
| Sep 20 |
NovaBay Pharmaceuticals to sell Avenova assets for $9.5M
|
| Sep 20 |
NovaBay Pharmaceuticals Signs Definitive Agreement to Sell its Avenova Assets
|
| Aug 14 |
NovaBay Pharmaceuticals, Inc. (NBY) Q2 2024 Earnings Call Transcript
|
| Aug 13 |
NovaBay GAAP EPS of -$1.37 misses by $0.14, revenue of $2.4M misses by $0.75M
|
